Biosimilar Remsima comparable to Remicade in RA crossover study
Published: 2013-11-01 06:59:00
Updated: 2013-11-01 06:59:00
Korean biotechnology company Celltrion presented results of its crossover trial for its biosimilar Remsima (infliximab candidate) at the American College of Rheumatology (ACR) 2013 Conference, which was held in San Diego on October 28-30.
According to Celltrion, results from the crossover stud...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
